In a recent study following individuals with ALPS over 20 years compared with healthy mutation-positive relatives, Priceet al. suggest that a novel biomarker signature, including elevated levels of soluble IL-10, IL-18, sFASL, and vitamin B12 measured in plasma/serum, can make a presumptive diagnosis of ALPS16. Here, IL10 is linked to autoimmune lymphoproliferative syndrome.